- socially bharat
- September 13, 2024
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in